- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04102241
Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis
October 11, 2021 updated by: Tianjin Hemay Pharmaceutical Co., Ltd
A Phase Ⅱ Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis
Hemay005 is a novel phosphodiesterase type 4(PDE4) inhibitor being developed for the treatment of psoriasis.After single asending dose and mutiple asending dose in health subjects.
And the patients with moderate to severe plaque psoriasis will be randomized into 4 cohorts(15mg, 30mg, 60mg and placebo) approximately 216 subjects will be enrolled (52 for each cohort ).
This study includes an 16-week treatment Period, then a 36-week Treatment Period without placebo.
Study Overview
Study Type
Interventional
Enrollment (Actual)
216
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- Second Affiliated Hospital, School of Medicine, Zhejiang University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female at least 18 years of age and less than or equal to 75;
- Diagnosed with plaque psoriasis more than 6 months;
- Screening and baseline PSAI ≥12, sPGA≥3(Moderate to Severe),affected body surface area BSA≥10%;
- Investigator determined suitable for systemic treatment of psoriasis;
- All subjects must agree and commit to the use of a reliable contraceptive regimen. Women of childbearing potential must undergo monthly pregnancy testing during the study and agree to use two of the following methods of contraception throughout the study and for 90 days after the last dose of study drug. Reliable contraceptive regimen: vasectomy, abstinence, the use of condoms, intrauterine contraceptives (IUD), (Oral administration, patch, ring, injection, implantation) Barrier methods (diaphragm with spermicide, condom with spermicide);
- Ability to understand and be willing to sign a written informed consent before study entry.
Exclusion Criteria:
- Forms of psoriasis other than chronic plaque-type; (i.e., erythrodermic and guttate psoriasis, palmar, plantar or nail disease) at screening, Investigator diagnosed with drug-induced psoriasis (i.e., from beta-blockers, calcium channel inhibitors or lithium) prior to randomization;
- A history of chronic infection (i.e., tuberculosis);
- A condition of any skin disease(i.e., dermatitis) ;
- History of systemic autoimmune inflammatory disease that effect drug evaluation;
- Patients with an active infection who are assessed by the investigator as at increased risk;
- TB infection, high risk of acquiring TB infection, latent TB infection (LTBI), or current or history of NTMB infection;
- Subjects who used any of the following treatments : 2 weeks before randomize (including but not limited to local use of Glucocorticoids, topical retinoic acid preparations, vitamin D derivatives, tacrolimus, pimeklimus, dianthranol, etc) Except for the following situations: In the face, armpit and groin psoriasis skin lesions using weak or inefficient local use of glucocorticoid (efficacy grade 6-7) or scalp psoriasis skin lesions with coal tar shampoo, salicylic acid topical preparations, selenium disulfide, the use of non-pharmaceutical emollients (such as silicone cream, vitamin E cream, etc.) ; 4 weeks before randomize , Non-biological drug systemic therapy (including but not limited to systemic glucocorticoid, leflunomide, cyclophosphamide, methotrexate, cyclosporine, retinoic acid, traditional Chinese medicine decoction, proprietary Chinese medicine for the treatment of psoriasis, etc.), 2 weeks before randomize with UVB treatment, 4 weeks before randomize with psoralen and long wave ultraviolet (PUVA) therapy, 12 weeks before randomize with biological agents such as adamuzumab, enasip or infliximab, 24 weeks before randomize with alefacept, Briakinumab, Ustekinumab, Secukinumab; Subjects with psoriasis worsen or rebound 4 weeks before screening;
- Subjects who congenital or acquired immunodeficiency;
- Subjects couldn't limit their uv exposure during the study period (e.g. sunbathing and/or tanning devices);
- History of apremilast ;
- Subjects with conditions that may affect oral drug absorption, such as subtotal gastrectomy, clinically significant diabetic gastroenteropathy, or certain types of weight-loss surgery, such as gastric bypass surgery, do not include surgery that simply separates the stomach into separate Chambers, such as gastric banding surgery;
- sCr≥1.5 upper limit of normal (ULN); AST≥2ULN; ALT≥2 ULN
- WBC<3.0×109/L or WBC>14×109/L,PLT<100×109/L, Hb<85 g/L;
- Subjects with a malignant tumor, or any history of malignancy within 5 years (except skin squamous cell carcinoma in situ, basal cell carcinoma or cervical carcinoma in situ that has been treated and has no evidence of recurrence in the past 12 weeks);
- Subjects with positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B virus surface antigen, or hepatitis C virus antibody at screening;
- Has a history of alcohol or drug abuse or dependence, or a history of mental illness;
- Has committed suicide (Includes active attempts, discontinued attempts or attempted attempts) or suicidal thoughts within the past 6 months;
- Pregnant or lactating women or planning pregnancy during the study period;
- Know allergic to active ingredient or excipient of the investigational product;
- 4 weeks before randomize, participated in a clinical trial and use of the study drug;
- Accompanied by severe, progressive, or uncontrolled disease or in the investigator's opinion unsuitable to be enrolled.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
Patients with chronic plaque psoriasis will be treated BID for 16 weeks with placebo in first phase.
Then will be treated BID for 36-week extension followed with 30mg of Hemay005.
|
Placebos are the same as drugs, but contain no Hemay005.
Other Names:
|
EXPERIMENTAL: 15mg Hemay005
Patients with chronic plaque psoriasis will be treated BID for 16 weeks with 15mg Hemay005 in first phase.
Then will be treated BID for 36-week extension followed with 15mg of Hemay005.
|
Placebos are the same as drugs, but contain no Hemay005.
Other Names:
Hemay005 is a small molecule PDE4 inhibitor.
Other Names:
|
EXPERIMENTAL: 30mg Hemay005
Patients with chronic plaque psoriasis will be treated BID for 16 weeks with 30mg Hemay005 in first phase.
Then will be treated BID for 36-week extension followed with 30mg of Hemay005.
|
Placebos are the same as drugs, but contain no Hemay005.
Other Names:
Hemay005 is a small molecule PDE4 inhibitor.
Other Names:
|
EXPERIMENTAL: 60mg Hemay005
Patients with chronic plaque psoriasis will be treated BID for 16 weeks with 60mg Hemay005 in first phase.
Then will be treated BID for 36-week extension followed with 60mg of Hemay005.
|
Hemay005 is a small molecule PDE4 inhibitor.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects who have 75% or more reduction in [Psoriasis area-and-severity index score (PASI)] (PASI75).
Time Frame: week16
|
The proportion of subjects who have a reduction of 75% or more from baseline in the psoriasis area-and-severity index score (PASI 75) at week 16.
|
week16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Severity of Adverse Events and Serious Adverse Events.
Time Frame: week2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56.
|
Severity of all Adverse Events (AEs) and Serious Adverse Events (SAEs) that occur during the whole trial including the observational period (AEs and SAEs include but not limited to comorbidities, such as hypertension, diabetes, and cardiovascular diseases).
|
week2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56.
|
Cmax of Hemay005.
Time Frame: week8
|
Maximum observed serum concentration.
|
week8
|
Proportion of subjects achieving an overall sPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline.
Time Frame: week2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56.
|
The static Physician's Global Assessment (sPGA) rated the investigator's overall clinical assessment of a participants plaque thickness, erythema, and scaling on a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (majority of plaques have severe thickness, erythema, and scale).
To assign a sPGA score, the investigator examined all psoriatic lesions and assigned a severity score ranging from 0 to 5 for thickness, erythema, and scaling.
Scores for thickness, erythema, and scaling are summed and the mean of these 3 scores equals the overall sPGA score.
Decreases in sPGA correspond to clinical improvement.
|
week2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Min Zheng, Dr, Second Affiliated Hospital, School of Medicine, Zhejiang University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
May 30, 2019
Primary Completion (ACTUAL)
October 12, 2020
Study Completion (ACTUAL)
July 21, 2021
Study Registration Dates
First Submitted
March 20, 2019
First Submitted That Met QC Criteria
September 23, 2019
First Posted (ACTUAL)
September 25, 2019
Study Record Updates
Last Update Posted (ACTUAL)
October 13, 2021
Last Update Submitted That Met QC Criteria
October 11, 2021
Last Verified
October 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HM005PS2S01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis
-
ProgenaBiomeRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaUnited States
-
Clin4allRecruitingPsoriasis of Scalp | Psoriasis Nail | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrance
-
Innovaderm Research Inc.CompletedScalp Psoriasis | Pustular Palmo-plantar Psoriasis | Non-pustular Palmo-plantar Psoriasis | Elbow Psoriasis | Lower Leg PsoriasisCanada
-
Centre of Evidence of the French Society of DermatologyRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis PustularFrance
-
UCB Biopharma S.P.R.L.CompletedModerate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic PsoriasisJapan
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
-
Janssen Pharmaceutical K.K.RecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Eli Lilly and CompanyCompletedGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
TakedaRecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Herlev and Gentofte HospitalRecruitingMyocardial Infarction | Myocardial Ischemia | Heart Diseases | Cardiovascular Diseases | Heart Failure | Stroke | Psoriasis | Heart Failure, Diastolic | Psoriasis Vulgaris | Cardiovascular Risk Factor | Heart Failure, Systolic | Left Ventricular Dysfunction | Psoriasis Universalis | Psoriasis Face | Psoriasis Diffusa | Psoriasis... and other conditionsDenmark
Clinical Trials on Placebos
-
Yiling Pharmaceutical Inc.Completed
-
Nova Scotia Health AuthorityRecruiting
-
Beth Israel Deaconess Medical CenterTerminated
-
Intra-Cellular Therapies, Inc.CompletedBipolar Depression | Major Depressive DisorderUnited States, Bulgaria, Russian Federation, Serbia, Ukraine
-
Josef Smolen, Univ. Prof. Dr.Unknown
-
GE HealthcareSyneos HealthTerminatedChronic Kidney DiseasesUnited States, Spain, Belgium, Canada, Poland, United Kingdom
-
Viela BioCTI Clinical Trial and Consulting ServicesTerminated
-
Nanjing Sanhome Pharmaceutical, Co., Ltd.Completed
-
Viking Therapeutics, Inc.Active, not recruitingNASH - Nonalcoholic SteatohepatitisUnited States, Belgium, France, Mexico, Puerto Rico
-
Shengjing HospitalEnrolling by invitation